=> s gaagcctattctgcaaagattgc/sqsn L1 24 GAAGCCTATTCTGCAAAGATTGC/SQSN

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
29.16 32.52

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:32:03 ON 29 JUL 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Jul 2002 VOL 137 ISS 5 FILE LAST UPDATED: 28 Jul 2002 (20020728/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 11 L2 17 L1

=> d 1-17 ti

- L2 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2002 ACS
- TI Methods and compositions for diagnosing and treating rheumatoid arthritis
- L2 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2002 ACS
- TI Measurement of DNA methylation for analysis of the toxicology of substances
- L2 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS
- TI Cancer gene determination and therapeutic screening using signature gene sets
- L2 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS
- TI Gene expression profiles in hepatocellular carcinoma and metastatic liver cancer
- L2 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2002 ACS
- TI Gene expression profiles in granulocytic cells and in neutrophils exposed to Escherichia coli and/or Yersinia pestis
- L2 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS
- TI Nucleic acid compositions, kits, and methods for identification, assessment, prevention, and therapy of human breast cancer

ANSWER 7 OF 17 CAPLUS COPYRIGHT 2002 ACS L2 Human stress genes identified using DNA microarrays TI ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS T.2 Genetic polymorphisms in genes associated with drug metabolism and their ΤI use in selecting drug therapies ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS T₂ Genes differentially expressed in human foam cell differentiation ΤI ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS L2Nucleic acid compositions, kits, and methods for identification, TΙ assessment, prevention, and therapy of human breast cancer ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS L2Nucleic acid markers useful for the identification, assessment, prevention TI and therapy of human cancers ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS L2 Differential gene expression in mesothelioma ΤI ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS L2 Quantitation of dihydropyrimidine dehydrogenase expression by real-time TТ reverse transcription polymerase chain reaction ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS L2 cDNA cloning of bovine liver dihydropyrimidine dehydrogenase TIANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS L2Cloning and expression of a cDNA for human dihydropyrimidine dehydrogenase ΤI and its use in preventing reactions to 5-fluorouracil ANSWER 16 OF 17 CAPLUS COPYRIGHT 2002 ACS L2 Dihydropyrimidine dehydrogenase compositions and methods of use for TI fluorouracil dose optimization in cancer treatment and for immunoassay ANSWER 17 OF 17 CAPLUS COPYRIGHT 2002 ACS L2 cDNA cloning and chromosome mapping of human dihydropyrimidine ΤI dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria => d 4, 15 bib abANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS L2 2002:276203 CAPLUS AN DN 136:290017 Gene expression profiles in hepatocellular carcinoma and metastatic liver TΙ cancer Horne, Darci; Alvares, Christopher; Peres da Silva, Supriya; Vockley, IN Joseph G. Gene Logic, Inc., USA PAPCT Int. Appl., 298 pp. SO CODEN: PIXXD2 Patent DTEnglish LΑ FAN.CNT 1 APPLICATION NO. DATE KIND DATE PATENT NO. -----WO 2001-US30589 20011002 A2 20020411 WO 2002029103 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
        BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                            20001002
                      Ρ
PRAI US 2000-237054P
    The present invention identifies the global changes in gene expression
AΒ
    assocd. with liver cancer by examg. gene expression in tissue from normal
    liver, metastatic malignant liver and hepatocellular carcinoma (HCC).
    Gene signatures were obtained by hybridizing cDNA from liver samples mRNA
     onto the Affymetrix HuGeneFl array and the Human Hu35k set of arrays.
    There are 8479 genes and ESTs in the pos. Gene Signature for the HCC
     tumors, and a total of 23,233 genes and ESTs are included in the neg. Gene
     Signature of the HCC samples (e.g., all the genes that have been
     completely turned off during tumorigenesis, as well as those genes that
     are not usually expressed in liver tissue). A differential comparison of
     the genes and ESTs expressed in the normals and the two different types of
     liver tumors identifies a subset of the genes included in the pos. Gene
     Signatures that are uniquely expressed in each sample set. A no. of the
     tumor-expressing genes are closely examd. to det. if their expression
     patterns correlate with previous reports published in the literature, and
     to define a logical relationship between the gene and
     hepatocarcinogenesis. The present invention also identifies expression
     profiles which serve as useful diagnostic markers as well as markers that
     can be used to monitor disease states, disease progression, drug toxicity,
     drug efficacy and drug metab.
     ANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS
L2
     1996:357140 CAPLUS
AN
     125:29119
DN
     Cloning and expression of a cDNA for human dihydropyrimidine dehydrogenase
TI
     and its use in preventing reactions to 5-fluorouracil
     Gonzalez, Frank J.; Fernandez-Salguero, Pedro
IN
     United States Dept. of Health and Human Services, USA
PΑ
     PCT Int. Appl., 78 pp.
SO
     CODEN: PIXXD2
     Patent
DT
LΑ
     English
FAN.CNT 1
                                                            DATE
                                           APPLICATION NO.
                      KIND DATE
     PATENT NO.
                                           _____
                      ____
                                           WO 1995-US12016 19950907
                            19960321
                       A2
     WO 9608568
PΙ
                            19960517
     WO 9608568
                      Α3
             AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
             GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             TJ, TM
         RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
             LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
             SN, TD, TG
                                           US 1994-304309
                                                             19940912
                             19990105
     US 5856454
                       Α
                                           CA 1995-2199808
                                                            19950907
     CA 2199808
                       AΑ
                             19960321
                                           AU 1995-36801
                                                             19950907
                             19960329
     AU 9536801
                       A1
                             19980423
                       B2
     AU 690347
                                           EP 1995-934477
                                                            19950907
                             19970723
                       A2
     EP 784687
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
                                           US 1997-991942 19971216
                            20000118
     US 6015673
                       Α
                            19940912
PRAI US 1994-304309
                       Α
                       W
                            19950907
     WO 1995-US12016
```

Methods and compns. that are useful for detecting deficiencies in AΒ dihydropyrimidine dehydrogenase (DPD) levels in mammals including humans are described. Cancer patients having a DPD deficiency are at risk of a severe toxic reaction to the commonly used anticancer agent 5-fluorouracil (5-FU). DPD genes from human and pig are cloned and characterized and PCR methods and primers for detecting the level of DPD mRNA in a patient are designed. Also claimed are methods for expressing DPD genes in transgenic organisms. Expression vectors that employ a DPD nucleic acid as a selectable marker are also claimed. This selectable marker functions in both prokaryotes and eukaryotes. The pig cDNA was cloned from a liver expression library in .lambda.gtll by antibody screening. Mapping of the human gene and expression of the swine cDNA in Escherichia coli using a trp-lac promoter are demonstrated. The enzyme manufd. in E. coli used the same ping-pong mechanism as the native swine liver enzyme. One case of DPD deficiency in human was found to be due to deletion of an exon.